The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
Open accessAbstract
Background & Aims The efficacy of treatment of Helicobacter pylori infection has decreased steadily due to increasing resistance to clarithromycin, metronidazole, and levofloxacin. Resistance to amoxicillin is generally low, and high intragastric pH increases the efficacy of amoxicillin, so we investigated whether a combination of a high-dose proton-pump inhibitor and amoxicillin (dual therapy) was more effective than standard first-line or rescue therapies in eradicating H pylori. Methods We performed a large-scale, multi-hospital trial to compare the efficacy of a high-dose dual therapy (HDDT) with that of standard therapies in treatment-naïve (n=450) or treatment-experienced (n=168) patients with H pylori infection. Treatment-naïve patients were randomly assigned to groups given HDDT (rabeprazole 20 mg and amoxicillin 750 mg, 4 times/day for 14 days; group A1), sequential therapy for 10 days (group B1), or clarithromycin-containing triple therapy for 7 days (group C1). Treatment-experienced patients were randomly assigned to groups given HDDT for 14 days (group A2), sequential therapy for 10 days (B2), or levofloxacin-containing triple therapy for 7 days (C2). H pylori infection was detected using the 13C–urea breath test. We evaluated factors associated with treatment outcomes. Results In the intention-to-treat treat analysis, H pylori was eradicated in 95.3% of patients in group A1 (95% confidence interval [CI], 91.9%–98.8%), 85.3% in B1 (95% CI, 79.6%–91.1%), and 80.7% in group C1 (95% CI, 74.3%–87.1%). Infection was eradicated in 89.3% of patients in group A2 (95% CI, 80.9%–97.6%), 51.8% in group B2 (95% CI, 38.3%–65.3%), and 78.6% (95% CI, 67.5%–89.7%). The efficacy of HDDT was significantly higher than that of currently recommended regimens, irrespective of CYP2C19 genotype. Bacterial resistance to drugs was associated with treatment failure. There were no significant differences between groups in adverse events or patient adherence. Conclusions HDDT is superior to standard regimens as empiric first-line or rescue therapy for H pylori infection, with similar safety profiles and tolerability. ClinicalTrials.gov no: NCT01163435.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and Grading of Gastritis: The Updated Sydney System
Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199610000-00001 · Cited by 5,185
Cited by
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.563 · Cited by 1,604
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J.-M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327745 · Cited by 1,533
Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., & Tacconelli, E. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.007 · Cited by 1,270
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Fallone, C. A., Chiba, N., van Zanten, S. V., Fischbach, L., Gisbert, J. P., Hunt, R. H., Jones, N. L., Render, C., Leontiadis, G. I., Moayyedi, P., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.04.006 · Cited by 927
for the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
Metadata
- Authors
- Yang, J.-C., Lin, C.-J., Wang, H.-L., Chen, J.-D., Kao, J. Y., Shun, C.-T., Lu, C.-W., Lin, B.-R., Shieh, M.-J., Chang, M.-C., Chang, Y.-T., Wei, S.-C., Lin, L.-C., Yeh, W.-C., Kuo, J.-S., Tung, C.-C., Leong, Y.-L., Wang, T.-H., & Wong, J.-M.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 13
- Issue
- 5
- Pages
- 895-905.e5
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2098162091
- Cited by
- 202
- References
- 1
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection. https://app.cochat.ai/papers/10.1016/j.cgh.2014.10.036
- The paper
- Yang, J.-C., Lin, C.-J., Wang, H.-L., Chen, J.-D., Kao, J. Y., Shun, C.-T., Lu, C.-W., Lin, B.-R., Shieh, M.-J., Chang, M.-C., Chang, Y.-T., Wei, S.-C., Lin, L.-C., Yeh, W.-C., Kuo, J.-S., Tung, C.-C., Leong, Y.-L., Wang, T.-H., & Wong, J.-M. (2015). High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2014.10.036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.